Hippocampal sparing radiotherapy for glioblastoma patients: a planning study using volumetric modulated arc therapy
- Resource Type
- Authors
- Matthias Söhn; Jan Hofmaier; Maximilian Niyazi; O. Dohm; Claus Belka; Markus Alber; Stefan Bächle; Katia Parodi; S. Kantz
- Source
- Radiation Oncology (London, England)
- Subject
- Adult
Male
medicine.medical_specialty
medicine.medical_treatment
VMAT
Hippocampal formation
Hippocampus
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Imaging, Three-Dimensional
Planning study
Hippocampal sparing
Hippocampus (mythology)
Medicine
Humans
Radiology, Nuclear Medicine and imaging
Rank correlation
Aged
Aged, 80 and over
business.industry
Brain Neoplasms
Research
Radiotherapy Planning, Computer-Assisted
Radiotherapy Dosage
Middle Aged
medicine.disease
Volumetric modulated arc therapy
Surgery
Clinical trial
Radiation therapy
Oncology
Radiology Nuclear Medicine and imaging
030220 oncology & carcinogenesis
Female
Radiotherapy, Intensity-Modulated
Radiotherapy, Conformal
business
Nuclear medicine
Glioblastoma
- Language
- English
- ISSN
- 1748-717X
Background The purpose of this study is to investigate the potential to reduce exposure of the contralateral hippocampus in radiotherapy for glioblastoma using volumetric modulated arc therapy (VMAT). Methods Datasets of 27 patients who had received 3D conformal radiotherapy (3D-CRT) for glioblastoma with a prescribed dose of 60Gy in fractions of 2Gy were included in this planning study. VMAT plans were optimized with the aim to reduce the dose to the contralateral hippocampus as much as possible without compromising other parameters. Hippocampal dose and treatment parameters were compared to the 3D-CRT plans using the Wilcoxon signed-rank test. The influence of tumour location and PTV size on the hippocampal dose was investigated with the Mann–Whitney-U-test and Spearman’s rank correlation coefficient. Results The median reduction of the contralateral hippocampus generalized equivalent uniform dose (gEUD) with VMAT was 36 % compared to the original 3D-CRT plans (p